Advertisement
RGEN vs WAT
Which Stock Would AI Choose? Repligen (RGEN) vs. Waters (WAT) Stock Comparison
Key Takeaways
- Repligen (RGEN) reported second-quarter 2026 revenue of $204 million, reflecting 12% year-over-year growth, supported by its bioprocessing focus and a pending $1.5 billion acquisition of BioLife Solutions.
- Waters (WAT) prepares for its second-quarter 2026 earnings release on August 4, with analyst expectations for EPS of $3.01 and revenue of $1.62 billion, alongside recent product launches in clinical diagnostics.
- Both companies operate in the life sciences sector but differ in core exposure: RGEN emphasizes bioprocessing technologies for biologics manufacturing, while WAT provides analytical instruments for research and quality control.
- Recent market activity shows RGEN benefiting from M&A (mergers and acquisitions) momentum, whereas WAT maintains steady positioning ahead of earnings with new instrument introductions.
- Sector sentiment remains influenced by broader biotech and pharmaceutical spending trends, with relative performance tied to individual catalysts rather than uniform sector tailwinds.
- Investors may weigh RGEN’s expansion through acquisition against WAT’s established instrumentation franchise and upcoming financial results for comparative insights.
Introduction
This comparison examines Repligen (RGEN) and Waters (WAT), two companies serving distinct segments of the life sciences industry. Repligen specializes in bioprocessing solutions essential for biologic drug production, while Waters focuses on analytical instruments used in research, development, and quality assurance. The analysis is relevant for traders and investors monitoring life sciences equities, particularly those evaluating growth drivers such as acquisitions, earnings releases, and product innovations within the current market environment. By reviewing recent performance and positioning, market participants can assess relative strengths without reliance on forward projections.
RGEN Overview and Recent Performance
Repligen Corporation develops and commercializes bioprocessing technologies that support the manufacture of biologic drugs. In recent weeks, the company announced its acquisition of BioLife Solutions, a move expected to expand capabilities in cell and gene therapy biopreservation. On July 28, 2026, Repligen reported second-quarter revenue of $204 million, up 12% year-over-year on a reported basis and 13% organically. Additional developments include the opening of a European Training & Innovation Center and the publication of its 2025 Corporate Sustainability Report. These factors have contributed to sentiment around operational expansion and integration opportunities in the bioprocessing space.
WAT Overview and Recent Performance
Waters Corporation supplies analytical instruments, including liquid chromatography and mass spectrometry systems, primarily for pharmaceutical, academic, and industrial applications. In recent market activity, the company has highlighted a new highly sensitive clinical in vitro diagnostic (IVD) system launch aimed at enhancing its position in clinical testing. Waters is scheduled to report second-quarter 2026 results on August 4, with consensus expectations for earnings per share (EPS) of $3.01 and revenue of $1.62 billion. Performance in recent weeks has reflected preparation for these results alongside steady demand for its instrumentation portfolio within research and quality-control workflows.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots drawn from hundreds available on the platform. These bots trade thousands of different tickers across varied strategies, timeframes, and performance profiles, with only the strongest and most aligned with prevailing market conditions featured in the trending section. Available bots display a range of statistics, including win rates, profit factors, and drawdown metrics, allowing users to compare different trading styles and ticker sets. The section provides an informational overview of these tools for market participants interested in algorithmic approaches. Review the full selection at Trending AI Robots.
Head-to-Head Comparison
Repligen (RGEN) and Waters (WAT) both serve life sciences customers yet pursue different business models. RGEN centers on consumables and systems for bioprocessing in biologics production, with recent momentum driven by the announced BioLife acquisition that broadens its cell therapy exposure. WAT emphasizes capital equipment and software for analytical testing, supported by ongoing product innovation such as the new clinical IVD system. Sector exposure overlaps in pharmaceuticals but diverges in emphasis—manufacturing support versus research instrumentation. Recent momentum for RGEN ties to M&A (mergers and acquisitions) activity, while WAT’s positioning reflects earnings anticipation and product updates. Risk factors include integration challenges for RGEN’s acquisition and demand variability for WAT’s instruments amid research spending cycles. Market sentiment has responded to company-specific developments rather than uniform sector trends.
Tickeron AI Verdict
Based on observable factors such as recent earnings delivery, acquisition catalysts, and upcoming financial releases, Tickeron’s AI models indicate a probabilistic preference toward Repligen (RGEN) in the near term due to demonstrated revenue growth and strategic expansion activity. Waters (WAT) maintains competitive positioning through its instrumentation franchise and product pipeline ahead of earnings. The assessment reflects relative trend consistency and catalyst visibility without implying definitive outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGEN is a Buy and WAT is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RGEN’s FA Score shows that 0 FA rating(s) are green whileWAT’s FA Score has 2 green FA rating(s).
- RGEN’s FA Score: 0 green, 5 red.
- WAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RGEN’s TA Score shows that 4 TA indicator(s) are bullish while WAT’s TA Score has 5 bullish TA indicator(s).
- RGEN’s TA Score: 4 bullish, 4 bearish.
- WAT’s TA Score: 5 bullish, 4 bearish.
Price Growth
RGEN (@Pharmaceuticals: Other) experienced а +16.23% price change this week, while WAT (@Medical Specialties) price change was +7.83% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.28%. For the same industry, the average monthly price growth was +5.47%, and the average quarterly price growth was +2.65%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +6.88%. For the same industry, the average monthly price growth was +8.02%, and the average quarterly price growth was +20.04%.
Reported Earning Dates
RGEN is expected to report earnings on Nov 03, 2026.
WAT is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+4.28% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+6.88% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| RGEN | WAT | RGEN / WAT | |
| Capitalization | 9.25B | 39.9B | 23% |
| EBITDA | 172M | 991M | 17% |
| Gain YTD | 0.024 | 7.116 | 0% |
| P/E Ratio | 224.52 | 103.00 | 218% |
| Revenue | 785M | 3.77B | 21% |
| Total Cash | 810M | 462M | 175% |
| Total Debt | 691M | 5.57B | 12% |
RGEN | WAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 87 | |
SMR RATING 1..100 | 90 | 85 | |
PRICE GROWTH RATING 1..100 | 39 | 20 | |
P/E GROWTH RATING 1..100 | 100 | 4 | |
SEASONALITY SCORE 1..100 | 43 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
WAT's Valuation (75) in the Medical Specialties industry is in the same range as RGEN (83) in the Biotechnology industry. This means that WAT’s stock grew similarly to RGEN’s over the last 12 months.
WAT's Profit vs Risk Rating (87) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that WAT’s stock grew similarly to RGEN’s over the last 12 months.
WAT's SMR Rating (85) in the Medical Specialties industry is in the same range as RGEN (90) in the Biotechnology industry. This means that WAT’s stock grew similarly to RGEN’s over the last 12 months.
WAT's Price Growth Rating (20) in the Medical Specialties industry is in the same range as RGEN (39) in the Biotechnology industry. This means that WAT’s stock grew similarly to RGEN’s over the last 12 months.
WAT's P/E Growth Rating (4) in the Medical Specialties industry is significantly better than the same rating for RGEN (100) in the Biotechnology industry. This means that WAT’s stock grew significantly faster than RGEN’s over the last 12 months.
| RGEN | WAT | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 88% | 3 days ago 69% |
| Stochastic ODDS (%) | 3 days ago 86% | 3 days ago 72% |
| Momentum ODDS (%) | 3 days ago 73% | 3 days ago 63% |
| MACD ODDS (%) | 3 days ago 79% | 3 days ago 57% |
| TrendWeek ODDS (%) | 3 days ago 72% | 3 days ago 63% |
| TrendMonth ODDS (%) | 3 days ago 71% | 3 days ago 60% |
| Advances ODDS (%) | 3 days ago 74% | 5 days ago 62% |
| Declines ODDS (%) | 14 days ago 81% | 7 days ago 64% |
| BollingerBands ODDS (%) | 3 days ago 83% | 3 days ago 87% |
| Aroon ODDS (%) | 3 days ago 78% | N/A |
Advertisement
WAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, WAT has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | +1.79% | ||
| A - WAT | 68% Closely correlated | +3.28% | ||
| RVTY - WAT | 64% Loosely correlated | +0.37% | ||
| TMO - WAT | 60% Loosely correlated | +2.41% | ||
| BRKR - WAT | 58% Loosely correlated | +4.17% | ||
| CRL - WAT | 56% Loosely correlated | +0.75% | ||
More | ||||